NU/1246-5 PEPMOTEC (2) Commercialisation of university research through provision of management skills to assist in successful spin-out company creation

Dr Steven Cobb of Durham University has developed a novel chemical synthesis pathway that overcomes some well-known limitations of current methods of producing modified and cyclic therapeutic peptides. The proposal is to set up a company ("Pepmotec") to exploit the commercial opportunities presented by a core technology platform which is protected by two related patent families. The technology has considerable potential for use in the production of novel peptides for drug discovery as well as re-engineering existing candidate therapeutic peptides and established protein therapeutics to enhance stability, safety and effectiveness. The business will initially seek to use its core IP and know…

Read all of it on Contracts Finder →